TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
https://european-biotechnology.com/wp-content/uploads/2024/04/Neuraxapharm.jpg4451440Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-08-01 16:10:462024-07-09 15:06:53Neuraxpharm pays US$650m for MS drug commercialisation